A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2
18+
23 sites in AZ, CA, FL +11
About this study
This Phase 2 study is focused on people with multiple myeloma. The primary outcome being measured is Overall Response Rate (ORR).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Overall Response Rate (ORR)
Secondary: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score, Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Score, Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score, Complete Response (CR) or Better Rate, Duration of Response (DoR), Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity, Overall Survival (OS), Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
Oncology